Reata Announces RTA 744 Entering Clinical Development, Name Change

Reata Pharmaceuticals announced that its lead development candidate, RTA 744, has received FDA clearance to begin clinical testing in patients with advanced brain cancers. Additionally, the company has announced a change in its name from Reata Discovery to Reata Pharmaceuticals, to reflect the clinical status of its drug development programs.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19970820&full=1)